According to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax (R) SM) had estimated annual sales of $29 million in the U.S.

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New ...

Ophthalmic disease zero-shot question answering aims to answer questions about ophthalmic disease in natural language without any model training. Although the pretrained large language models (LLMs) ...

Aims Topical ciclosporin A (CsA) is a therapeutic option for dry eye disease (DED) to control ocular surface inflammation and improve tear function. The aim of this study is to systematically review ...

The following are safe ophthalmic preparations: Ciloxan® ophthalmic ointment and solution (cipro-floxacin), Vigamox® ophthalmic solution (moxifloxacin), Ocuflox® ophthalmic solution (ofloxacin ...

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal ...

Company News Published 06/09/2025, 07:05 AM 0 Harrow secures US rights to new ophthalmic steroid BYQLOVI 6838 -0.66% ...